VialVIAL
Home/Compounds/Navitoclax
MetabolicIn Clinical TrialsPreclinical

Navitoclax

Regulatory

Legal Status in 2026

In Clinical Trials

In active US clinical trials (Phase 2 or later); no FDA approval yet.

This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.

About

About Navitoclax

Navitoclax (ABT-263) is a BCL-2/BCL-xL inhibitor originally developed as a cancer therapeutic that has demonstrated potent senolytic activity in preclinical aging models, extending lifespan and improving physical function in aged mice. Its clinical use in oncology is limited by platelet toxicity, but intermittent low-dose longevity protocols are being investigated to harness senolytic benefits while minimizing hematological side effects.

Science

Mechanism of Action

Directly inhibits BCL-2 and BCL-xL anti-apoptotic proteins that senescent cells abnormally upregulate as part of their senescence-associated anti-apoptotic program, restoring apoptosis sensitivity and enabling selective senescent cell clearance.

Dosing

Typical Protocol

Not established for longevity use; oncology doses are 150–325 mg daily. Intermittent protocols are experimental and physician-supervised only.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Evidence

Evidence Tier

Preclinical

Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.

Availability

Provider availability

Navitoclax is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.

This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.